ESR1 and breast carcinoma: Immunohistochemical (IHC) analysis of ER− versus ER+ breast tumors from patients showed that 37/83 or 45% of ER+ breast cancers had low or undetectable STAT1, while 17/78 or 22% of ER− breast cancers had low to undetectable STAT1 [7].